Table 2 IGF-I during GH treatment according to randomization group

At GH start

71

−1.2 ± 1.59

32

−1.4 ± 1.51

20

−0.9 ± 1.66

19

−1.1 ± 1.66

−1 ± 1.64

1^st year after GH start

76

0.9 ± 1.71

28

0.9 ± 1.37

24

1 ± 1.95

24

0 ± 1.89

0.9 ± 1.9

ΔIGF-I_SDS, 1^st year after GH start

63

2.1 ± 1.48

25

2.2 ± 1.37

19

1.9 ± 1.94

19

2.1 ± 1.1

2 ± 1.56

Last pre-pubertal

90

1.2 ± 1.23

35

1.1 ± 1.15

28

1.1 ± 1.33

27

1.4 ± 1.26

1.3 ± 1.29

IGF-I_SDS prepubertal level

100

0.8 ± 1.07

37

0.6 ± 1.08

30

0.9 ± 1.05

33

1 ± 1.08

1 ± 1.06

Study start

104

0.9 ± 1.21

38

1 ± 1.02

30

0.8 ± 1.33

36

1 ± 1.29

0.9 ± 1.31

1^st year after study start

100

1.2 ± 1.07

36

0.9 ± 0.88

30

1.3 ± 1.15

34

1.5 ± 1.13^*

1.4 ± 1.13^**

ΔIGF-I_SDS 1^st year after study start

100

0.3 ± 0.98

36

−0.1 ± 0.96

30

0.5 ± 1.09^****

34

0.4 ± 0.78^****

0.5 ± 0.93^*

IGF-I_SDS pubertal level

104

1 ± 0.95

38

0.9 ± 0.67

30

1.1 ± 1.14

36

1.1 ± 1.03

1.1 ± 1.07

ΔIGF.I_SDSPubertal level from study start

104

0.1 ± 0.92

38

−0.2 ± 0.86

30

0.4 ± 1.1^***

36

0.1 ± 0.75^*****

0.2 ± 0.92

Before study stop

104

0.6 ± 1.36

38

0.6 ± 1.18

30

0.9 ± 1.29

36

0.3 ± 1.57

0.6 ± 1.46

After study stop

65

−0.4 ± 1.54

23

−0.1 ± 0.91

18

−0.3 ± 1.4

24

−0.6 ± 2.04

−0.5 ± 1.78